Genkyotex announced the closing of the acquisition by Calliditas Therapeutics AB (“Calliditas”) of 62.7% of Genkyotex in an off-market transaction. Following the closing of the off-market block trade, the members of the board of directors members other than Mr. Elias Papatheodorou, Chief Executive Officer, have resigned. Mr. Elmar Schnee, Chairman of the board of Calliditas, Mrs. Renée Aguiar-Lucander, Chief Executive Officer of Calliditas and Mr. Jonathan Schur, Group General Counsel of Calliditas, have been coopted as members of the Board of directors. Mr. Elmar Schnee has been elected President of the Board of directors.